Поисковый запрос: (<.>S=ТАДАЛАФИЛ<.>) |
Общее количество найденных документов : 46
Показаны документы с 1 по 20
|
|
1.
| Rabinowitz Joshua D. Delivery of erectile dysfunction drugs through an inhalation route
|
2.
| Teixeira Cleber E. Differential effects of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, and tadalafil in rat aorta // J. Pharmacol. and Exp. Ther., 2006. Vol. 316, N 2.-С.654-661
|
3.
| Dried blood spot technique for the monitoring of ambrisentan, bosentan sildenafil, and tadalafil in patients with pulmonary arterial hypertension // Anal. Chem., 2015. Vol. 87, N 24.-С.12112-12120
|
4.
| Efficacy and safety of long-term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction // Andrologia, 2015. Vol. 47, N 1.-С.20-24
|
5.
| Efficacy of oral tadalafil, a new long-acting phosphodiesterase-5 inhibitor, for the short-term treatment of pulmonary arterial hypertension in a dog // J. Vet. Med. A, 2006. Vol. 53, N 3.-С.129-133
|
6.
| Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension // Brit. J. Clin. Pharmacol., 2006. Vol. 62, N 3.-С.280-287
|
7.
| L-норвалин и тадалафил - персективные эндотелиопротекторы // Теоретические и практические проблемы развития современной науки. -Махачкала, 2014.-С.179-180
|
8.
| Levien Terri L. Phosphodiesterase inhibitors in Raynaud's phenomenon // Ann. Pharmacother., 2006. Vol. 40, N 7-8.-С.1388-1393
|
9.
| Gales Barry J. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men // Ann. Pharmacother., 2008. Vol. 42, N 1.-С.111-115
|
10.
| Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud's phenomenon: Systematic review and meta-analysis of randomised trials // Ann. Rheum. Diseases, 2013. Vol. 72, N 10.-С.1696-1699
|
11.
| Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil // J. Pharmacol. and Exp. Ther., 2008. Vol. 325, N 1.-С.62-68
|
12.
| Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil // Eur. J. Pharm. and Biopharm., 2015. Vol. 94.-С.106-115
|
13.
| Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis // J. Rheumatol., 2009. Vol. 36, N 10.-С.2264-2268
|
14.
| Ismail H. Recurrent epistaxis after treatment with tadalafil (Cialis) // Acta oto-laryngol., 2005. Vol. 125, N 3.-С.334-335
|
15.
| Srinivas Nuggehally R. Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors - assembling the clues // Brit. J. Clin. Pharmacol., 2009. Vol. 67, N 4.-С.475-477
|
16.
| Srinivas Nuggehally R. Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors - assembling the clues // Brit. J. Clin. Pharmacol., 2009. Vol. 67, N 4.-С.475-477
|
17.
| Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility. A case report // Dig. Diseases and Sci., 2005. Vol. 50, N 11.-С.2059-2062
|
18.
| Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility. A case report // Dig. Diseases and Sci., 2005. Vol. 50, N 11.-С.2059-2062
|
19.
| Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents // Arzneim.-Forsch., 2009. Vol. 59, N 8.-С.415-421
|
20.
| Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents // Arzneim.-Forsch., 2009. Vol. 59, N 8.-С.415-421
|
|
|
|
Главная
Назад
"Электронные каталоги и базы данных библиотек СО РАН"